Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

COVID-19 is a tricky virus, it changes and evolves all the time. So, as we learn in this story, we can’t let our guard down.

Novavax's protein-based shot is an option for COVID vaccination this season, joining refreshed formulas from Moderna and ...

Shares of Novavax Inc. NVAX inched 0.15% higher to $13.04 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index COMP rising 1.45% ...

The FDA recently approved the updated mRNA Pfizer and Moderna boosters, as well as the updated Novavax COVID vaccine, to ...

In addition to Pfizer and Moderna's new formulas, Novavax's protein-based shot is an option for COVID vaccination this season ...

The Centers for Disease Control and Prevention (CDC) currently recommends that everyone aged 6 months and up get the Moderna or Pfizer COVID-19 vaccines. The Novavax vaccine is authorized by the U.S.

Shares of Novavax Inc. NVAX slid 4.34% to $13.02 Monday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index COMP falling 1.18% to 17,923.90 ...

Novavax's financial position improved significantly with a $570 million cash infusion from Sanofi. Find out why I remain ...

The mRNA-based supplier of vaccines profited from Covid-19 vaccine sales. As the years passed, Covid evolved. The weaker ...

Novavax (NVAX) shares soared 19.2% in the last trading session to close at $14.68. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares ...

In a report released today, Roger Song from Jefferies maintained a Buy rating on Novavax (NVAX – Research Report), with a price target of ...